Changes in symptom control, work productivity and activity impairment, and anxiety symptoms in chronic idiopathic urticaria patients after 24-week treatment with omalizumab

Category Primary study
JournalJournal of Managed Care and Specialty Pharmacy
Year 2017
This article has no abstract
Epistemonikos ID: 3e2021cd68979c94b6b0601708b0521313a4c0c6
First added on: Feb 09, 2025